pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Big Pharma · news · pharmadog
← back to Big Pharma
News · Big Pharma
94
stories
10h
Roche pours $750M into Oregon manufacturing plant as obesity push expands
biospace
20h
Chai tees up Bristol Myers Squibb AI antibody discovery collab
fiercebiotech
20h
Lilly pens deal with Gateway Labs alumni Amplitude for RNA vaccine platform for infectious disease
fiercebiotech
1d
Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategy
fiercebiotech
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
1d
Merck and Sarah Cannon team up to boost oncology trial efficiency
fiercebiotech
2d
Merck and Sarah Cannon team up to boost oncology trial efficiency
fiercebiotech
2d
BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca
fiercebiotech
3d
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
fiercebiotech
4d
‘Money has spoken’: Why Chinese biotech CEOs tell Fierce they’re unfazed about rising US tensions
fiercebiotech
6d
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
6d
Biotech initiatives pick up as more regions race to become hubs
biopharma dive
7d
Nascent US psychedelic therapy opportunity attracts overseas manufacturers
biospace
7d
Opinion: How to disrupt the health misinformation business model
stat
9d
With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
biospace
10d
Regeneron backs $75M series A for antibody upstart Infinimmune
fiercebiotech
11d
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
biospace
11d
Psychedelics on the cusp of market breakthrough as clinical, policy support grow
biospace
11d
Novo Nordisk and Amazon sign AI drug discovery pact, launch London innovation hub
fiercebiotech
13d
Why Big Pharma is chasing the industry’s most-powerful supercomputer
biopharma dive
13d
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
14d
CROs vs. biotechs: Finding the right fit
biospace
15d
‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E
fiercebiotech
15d
Over 1/3 stay in biopharma jobs for health insurance, poll finds
biospace
15d
Lilly drops another gene therapy trial from $1B Prevail buyout
fiercebiotech
16d
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
16d
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
fiercebiotech
16d
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
16d
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
16d
Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
biospace
← prev
page 1 of 4
next →
